Home/Filings/4/0001209191-21-066229
4//SEC Filing

Ostertag Eric 4

Accession 0001209191-21-066229

CIK 0001661460other

Filed

Nov 21, 7:00 PM ET

Accepted

Nov 22, 7:50 PM ET

Size

11.8 KB

Accession

0001209191-21-066229

Insider Transaction Report

Form 4
Period: 2021-11-19
Ostertag Eric
DirectorChief Executive Officer10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2021-11-19$9.15/sh+1,000$9,150697,422 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-11-191,000739,995 total
    Exercise: $9.15Exp: 2031-02-03Common Stock (1,000 underlying)
Holdings
  • Common Stock

    (indirect: See footnote)
    3,659,503
  • Common Stock

    (indirect: See footnote)
    3,358,455
  • Common Stock

    (indirect: See footnote)
    961,445
  • Common Stock

    (indirect: See footnote)
    629,194
  • Common Stock

    (indirect: See footnote)
    160,696
Footnotes (6)
  • [F1]The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
  • [F2]The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
  • [F3]The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
  • [F4]The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
  • [F5]The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
  • [F6]12.5% of the shares originally subject to the stock option vested and became exercisable on August 4, 2021, and the remaining shares vest in 42 equal monthly installments thereafter.

Issuer

Poseida Therapeutics, Inc.

CIK 0001661460

Entity typeother

Related Parties

1
  • filerCIK 0001765987

Filing Metadata

Form type
4
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 7:50 PM ET
Size
11.8 KB